| 產(chǎn)品描述： | AZD1208 is a novel, orally bioavailable, highly selective PIM kinase inhibitor with single nanomolar potency against all three PIM kinases. |
| 靶點(diǎn)： |
Apoptosis;Autophagy;Pim;Apoptosis;?Pim;?Autophagy |
| 體內(nèi)研究： |
AZD1208在培養(yǎng)的MOLM-16細(xì)胞中引起細(xì)胞周期停滯和細(xì)胞凋亡。 這伴隨著BAD,4EBP1和p70S6K磷酸化的劑量依賴性降低。 另外,AZD1208導(dǎo)致有效抑制來(lái)自骨髓抽吸物的原代AML細(xì)胞的集落生長(zhǎng)并下調(diào)Pim靶標(biāo)的磷酸化 |
| 細(xì)胞實(shí)驗(yàn)： |
AZD1208 is dissolved in DMSO. MOLM-16 cells, purchased from DSMZ and cultured in RPMI containing 10% fetal bovine serum (FBS) and 1% L-glutamine, are plated at 20,000 cells per well in 96 well plates overnight. Cells are treated for 72 hours with compound or control vehicle (dimethyl sulfoxide) and cell viability is measured after the addition of Cell Titer-Blue for 4 hours at 37?C and reading of fluorescence on a Tecan Infinite? 200. The GI50 is determined by calculating growth at each dose relative to vehicle treated cells and cell viability at the time of treatment. |
| 參考文獻(xiàn)： |
1.Erika Keeton, et al. 53rd ASH Annual Meeting (2011) Abstract nr 1540 |
| 溶解性： |
DMSO:7.6 mg/mL (20 mM)),with gentle warming |
| 保存條件： |
-20℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.635 ml |
13.176 ml |
26.352 ml |
| 5 mM |
0.527 ml |
2.635 ml |
5.27 ml |
| 10 mM |
0.264 ml |
1.318 ml |
2.635 ml |
| 50 mM |
0.053 ml |
0.264 ml |
0.527 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
危險(xiǎn)品化學(xué)品經(jīng)營(yíng)許可證（不帶存儲(chǔ)）
營(yíng)業(yè)執(zhí)照(三證合一)
掃一掃關(guān)注
北京